Back to Results
First PageMeta Content
Anilides / Ivacaftor / Phenols / Quinolones / Vertex Pharmaceuticals / VX-809 / Cystic fibrosis / VX / Cystic Fibrosis Foundation / Chemistry / Health / Organic chemistry


Microsoft Word - Document1
Add to Reading List

Document Date: 2013-02-26 23:38:03

Open Document

File Size: 30,19 KB

Share Result on Facebook

City

Cambridge / /

Company

Week Dosing Regimen Group / Cystic Fibrosis Foundation Therapeutics Inc. / Vertex Pharmaceuticals Incorporated / WithinGroup / Vertex / /

Continent

North America / Europe / /

Country

United States / Canada / Australia / United Kingdom / /

/

Event

FDA Phase / Product Issues / Conference Call / Business Partnership / /

IndustryTerm

treatment of hepatitis C / telephone commencing / conference call / /

MedicalCondition

chronic lung inflammation / pulmonary exacerbations / rheumatoid arthritis / hepatitis C / lung disease / Ivacaftor Cystic fibrosis / cystic fibrosis transmembrane conductance regulator / cystic fibrosis / infections / serious diseases / genetic disease / disease / chronic lung infections / diseases / pulmonary adverse event / /

MedicalTreatment

innovative therapies / /

Organization

European Medicines Agency / U.S. Food and Drug Administration / Cystic Fibrosis Foundation / Securities and Exchange Commission / /

Person

Robert Kauffman / Kelly Lewis / Megan Goulart / /

/

Position

Vice President and Chief Medical Officer / Private / /

Product

ivacaftor / VX-809 / CFTR genes / F508del / /

ProvinceOrState

Massachusetts / /

RadioStation

CFTR / /

Technology

MP3 / genotyping / pharmacokinetics / drug discovery / /

URL

www.vrtx.com / /

SocialTag